The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia-Reference-Cited by-同舟云学术

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia

Published:2022-04-11 Issue:4 Volume:12 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Lim Byungho^ORCID,Yoo Dabin,Chun Younghwa,Go Areum,Cho Kyung-Jin,Choi Daeun,Jung Myoung Eun,Lee Ha Young,Boohaker Rebecca J.,Lee Jin Soo,Jung DooYoung,Choi Gildon^ORCID

Funder

Korea Research Institute of Chemical Technology

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-022-00664-y.pdf

Reference12 articles.

1. Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.

2. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593–606.

3. Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, et al. Effectiveness and safety of therapeutic regimens for elderly patients with acute myeloid leukemia: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2018;18:e303–e14.

4. Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33:2795–804.

5. Santini V, Ossenkoppele GJ. Hypomethylating agents in the treatment of acute myeloid leukemia: a guide to optimal use. Crit Rev Oncol Hematol. 2019;140:1–7.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor biomarkers for diagnosis, prognosis and targeted therapy;Signal Transduction and Targeted Therapy;2024-05-20

2. Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer;Clinical Cancer Research;2024-01-17

3. Epigenetic regulation in cancer therapy: From mechanisms to clinical advances;MedComm – Oncology;2024-01-04

4. A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia;Investigational New Drugs;2023-09-13

5. Integrative Analyses Reveal the Anticancer Mechanisms and Sensitivity Markers of the Next-Generation Hypomethylating Agent NTX-301;Cancers;2023-03-13